Endothelins are proteins that constrict blood vessels and raise blood pressure. They are normally kept in balance by other mechanisms, but when they are over-expressed, they contribute to high blood pressure (hypertension) and heart disease.
Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.
A new drug is showing promise in shielding against the harmful effects of traumatic brain injury (TBI) in rats, according to a study that was released today and will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012.
Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.
People with diabetes are known to have an increased risk of heart disease. New research published in BioMed Central's open access journal BMC Medicine shows that regular consumption of a vitamin D-fortified yoghurt drink improves cholesterol levels and biomarkers of endothelial dysfunction, a precursor of heart disease, in diabetics.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.
United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.
Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.
Actelion Pharmaceuticals US, Inc. and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors for their efforts in advancing research in PAH. Each researcher will receive a 12-month mentored grant of up to $100,000 in support, funded through the ENTELLIGENCE program supported by Actelion. The announcement was made at an awards luncheon, during which the recipients of the 2011 awards gave an overview of their proposed work.
United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).
A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis.
United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.
The U.S. Food and Drug Administration today announced that monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), used to treat high blood pressure in the vessels that carry blood to the lungs (pulmonary arterial hypertension, or PAH).
Results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease were published this week in the Journal of the American Society of Nephrology. The published study results suggest that atrasentan, used in conjunction with renin-angiotensin system inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type 2 diabetes.
A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.
Scientists are learning more about how protein gets in the urine when the kidneys begin to fail and how a new drug blocks it.
A study in the Oct. 1 issue of the journal Sleep found that getting too little or too much sleep in early pregnancy is associated with elevated blood pressure in the third trimester. The study suggests that improving prenatal sleep hygiene may provide important health benefits.
A study of the body system that deals with Americans' love affair with salt may yield more insight into why so many end up hypertensive and how to better treat them.
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Actelion Ltd announced today that findings from the REVEAL Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension according to data presented at the American Thoracic Society's Annual International Conference.